logo: 16th St. Gallen International Breast Cancer Conference

16th St. Gallen International Breast Cancer Conference

Primary Therapy of Early Breast Cancer Vienna, Austria 20 - 23 March 2019

satellite symposia

Wednesday, 20 March 2019


10.30 – 12.00 h

Satellite symposium Touchime

What's on the horizon for high risk breast cancer in the adjuvant setting?


Introduction and welcome
Christoph Zielinski (Austria)


Potential of new targeted agents in high-risk early breast cancer – are we entering a new era?
Valentina Guarneri (Italy)


Questions from the audience


The high-risk early breast cancer patient – how can we apply a differentiated approach in the clinic?

Case presentations

Christoph Zielinski (Austria)
François-Clément Bidard (France)


Questions from the audience


Looking to the future…
Christoph Zielinski (Austria)


12.30 – 14.00h

Satellite symposium Genomic Health

Optimizing outcomes in early-stage breast cancer by tailoring the use of chemotherapy


When should we use chemotherapy in early-stage breast cancer?


  • Evidence on how to guide chemotherapy treatment decisions
  • A debate around patient cases proposed by a renowned panel


Expert Panel:

Ahmad Awada (Belgium)

Joseph Gligorov (France)

Antonio Llombart (Spain)

Ulrike Nitz (Germany)

Eric Winer (USA)




satellite symposia

Thursday, 21 March 2019


12.45 – 13.45 h

Satellite symposium Pfizer



CDK 4/6 inhibitors

Website prIME Oncology



Chair: Sibylle Loibl (Germany)  


Treating HR+/HER2- breast cancer: CDK4/6 inhibitors today and in the future

Sibylle Loibl (Germany)


Clinical benefit of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer – beyond PFS

Nicholas Turner (UK)


From trials to clinic: choosing the right treatment for the right patient

Guy Jerusalem (Belgium)





17.45 – 19.15 h

Satellite symposium F. Hoffmann-La Roche


Transforming the moment: Recent advances in early breast cancer management


Website prIME Oncology

Introduction and welcome

Sibylle Loibl (Germany)


Optimising treatment for patients with residual disease

Charles Geyer (USA)


Targeted therapies to tackle difficult diseases

Aleix Prat (Spain)


Transforming our outlook in a curative setting

Sibylle Loibl (Germany)




Summary & close

Sibylle Loibl (Germany)




Friday, 22 March 2019


12.45 – 13.45 h

Satellite symposium NanoString Technologies


Recent Breakthroughs for HR+/HER2-Early Breast Cancer Patients:
Accurate Risk Measurement and Local Testing with Prosigna



Prognostic performance in different clinical risk groups

Comparison among currently available multigene signatures

Prosigna real-world evidence and data

Value of intrinsic subtyping in clinical practice


Michael Gnant (Austria)


Moving to precision medicine: Clinical utility of molecular subtypes in breast cancer

Eva Ciruelos (Spain)


Supporting Prosigna clinical evidence with Real World Data from the Danish Breast Cancer Group

Bent Ejerletsen (Denmark)


Prosigna in the UK: NICE 2018 recommendation and OPTIMA trial

Andreas Makris (United Kingdom)




17.45 – 19.15 h
Satellite symposium prIME Oncology
Estrogen Receptor–Positive Early Breast Cancer: 
Developments in HER2+ and Younger Patient Subsets
Welcome and introduction
Sibylle Loibl (Germany)
Beat the experts interactive quiz
Sibylle Loibl (Germany)
The natural history and biology of ER+ breast cancer
Sherene Loi (Australia)
Strategies to improve the probability of cure from HER2+ early breast cancer
Javier Cortés (Spain)
Premenopausal ER+ breast cancer – Playing the long game
Olivia Pagani (Switzerland)
Adverse event management in early breast cancer
Angelo Di Leo (Italy)
Balancing benefits and risks in early breast cancer
Sibylle Loibl (Germany)
Conclusions and “prIME pointsTM
Sibylle Loibl (Germany)



* The accreditation organisation European Union of Medical Specialists requests that all information about industry related or sponsored satellite symposia has to be mentioned separately from the scientific program.
Rorschacherstr. 150
CH-9006 St. Gallen/Switzerland
Tel. +41 (0)71 243 00 32
Fax. +41 (0)71 245 68 05